• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

CD-PLLD co-delivering docetaxel and MMP-9 siRNA plasmid for nasopharyngeal carcinoma therapy in  vivo.
CD-PLLD co-delivering docetaxel and MMP-9 siRNA plasmid for nasopharyngeal carcinoma therapy in vivo. Mol Med Rep. 2017 Jun 07;: Authors: Liu T, Wu X, Wang Y, Hou X, Jiang G, Wu T, Xie H, Xie M Abstract The co-delivery of a drug and a target gene has become a primary strategy in cancer therapy. Based on our previous study, a synthesized star‑shaped co‑polymer consisting of β‑cyclodextrin (CD) and a poly(L‑lysine) dendron (PLLD) was used to co-deliver docetaxel (DOC) and matrix metalloproteinase 9 (MMP‑9) small interfering RNA, via CD‑PLLD/DOC/MMP‑9 complexes, into mice implanted with HN...
Source: Molecular Medicine Reports - October 29, 2017 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Folate-targeted star-shaped cationic copolymer co-delivering docetaxel and MMP-9 siRNA for nasopharyngeal carcinoma therapy.
Authors: Liu T, Wu X, Wang Y, Zhang T, Wu T, Liu F, Wang W, Jiang G, Xie M Abstract The co-delivery of drug and gene has become the primary strategy in cancer therapy. Based on our previous work, to co-deliver docetaxel (DOC) and MMP-9 siRNA more efficiently for HNE-1 nasopharyngeal carcinoma therapy, a folate-modified star-shaped copolymer (FA-CD-PLLD) consisting of β-cyclodextrin (CD) and poly(L-lysine) dendron (PLLD) was synthesized, and then used for DOC and MMP-9 co-delivery. Different from commonly used amphiphilic copolymers micelles, the obtained CD derivative could be used directly for the combinatorial d...
Source: Oncotarget - June 5, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Star-Shaped Amphiphilic Hyperbranched Polyglycerol Conjugated with Dendritic Poly(l-lysine) for the Codelivery of Docetaxel and MMP-9 siRNA in Cancer Therapy
ACS Applied Materials & InterfacesDOI: 10.1021/acsami.6b01611
Source: ACS Applied Materials and Interfaces - May 11, 2016 Category: Materials Science Authors: Xiaoyan Zhou, Qianqian Zheng, Changyong Wang, Jiake Xu, Jian-Ping Wu, Thomas Brett Kirk, Dong Ma and Wei Xue Source Type: research

The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics.
In conclusion, development of a novel 3D cell culture model of prostate cancer bone metastasis has been initiated resulting, for the first time, in the successful delivery of gene therapeutics in a 3D in vitro model. Further enhancement of this model will help elucidate the pathogenesis of prostate cancer and also accelerate the design of effective therapies which can penetrate into the bone microenvironment for prostate cancer therapy. PMID: 26196533 [PubMed - as supplied by publisher]
Source: Biomaterials - July 14, 2015 Category: Materials Science Authors: Fitzgerald KA, Guo J, Tierney EG, Curtin CM, Malhotra M, Darcy R, O'Brien FJ, O'Driscoll CM Tags: Biomaterials Source Type: research

Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines.
Authors: Yuan TM, Liang RY, Chueh PJ, Chuang SM Abstract The identification of prognostic markers and establishing their value as therapeutic targets improves therapeutic efficacy against human cancers. Ribophorin II (RPN2) has been demonstrated to be a prognostic marker of human cancer, including breast and pancreatic cancers. The present study aimed to evaluate RPN2 expression in gastric cancer and to examine the possible correlation between RPN2 expression and the response of cells to clinical anticancer drugs, which has received little research attention at present. The gastric cancer AGS, TMC-1, SNU-1, TMK-1, ...
Source: Oncology Letters - June 4, 2015 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Abstract 731: SRI-28731, a highly potent and selective MAP4K4 (HGK) inhibitor for cancer therapy
MAP4K4, a Ser/Thr kinase, was identified as an important pro-migratory kinase in an siRNA screen, targeting 5,234 human genes for modulators of tumor cell motility. MAP4K4 siRNA potently suppressed cell invasion and migration of multiple cancer cell lines, indicating a broad role in cell motility. There are no drugs in the clinic that are known to specifically target MAP4K4 for cancer therapy. We have successfully developed an orally active, highly effective and selective MAP4K4 inhibitor (SRI-28731) with potent in vitro and in vivo anticancer activity. SRI-28731 is more potent than Paclitaxel (Taxol) against most of the b...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Chang, C.-T., Park, J., Zhou, W., Liu, X., Sato, B., Dinh, D., Furimsky, A., Beviglia, L., Sambucetti, L., Jong, L. Tags: Experimental and Molecular Therapeutics Source Type: research

Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
CONCLUSIONS: These findings indicate that MSV/EphA2 merits further development as a novel therapeutic agent for ovarian cancer. PMID: 23386691 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 5, 2013 Category: Cancer & Oncology Authors: Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang GD, Guo X, Bao L, Guoting Q, Deng X, Li Q, Erm D, Sakamoto JH, Liu X, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G Tags: Clin Cancer Res Source Type: research